Latest Insider Transactions at Immunovant, Inc. (IMVT)
This section provides a real-time view of insider transactions for Immunovant, Inc. (IMVT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Immunovant, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Immunovant, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 27
2022
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
541
-0.19%
|
$2,164
$4.72 P/Share
|
|
Apr 19
2022
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,392
-0.71%
|
$5,568
$4.98 P/Share
|
|
Mar 24
2022
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
19,227
-3.33%
|
$96,135
$5.9 P/Share
|
|
Mar 24
2022
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
6,381
-2.2%
|
$31,905
$5.9 P/Share
|
|
Jan 28
2022
|
Mark S. Levine Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
143,000
+50.0%
|
-
|
|
Jan 10
2022
|
Atul Pande Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,726
+25.97%
|
-
|
|
Jan 10
2022
|
Douglas J. Hughes Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,726
+21.32%
|
-
|
|
Jan 10
2022
|
George V Migausky Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,726
+19.63%
|
-
|
|
Jan 10
2022
|
Andrew J. Fromkin Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,726
+24.37%
|
-
|
|
Jan 10
2022
|
Frank Torti Director |
BUY
Grant, award, or other acquisition
|
Direct |
100,126
+40.4%
|
-
|
|
Jan 07
2022
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
125,158
-17.8%
|
$876,106
$7.25 P/Share
|
|
Jan 07
2022
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
29,959
-14.79%
|
$209,713
$7.25 P/Share
|
|
Jan 07
2022
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
55,318
-16.04%
|
$387,226
$7.25 P/Share
|
|
Jan 05
2022
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
26,813
-11.96%
|
$214,504
$8.28 P/Share
|
|
Nov 05
2021
|
William L. Macias Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,108
+33.34%
|
-
|
|
Oct 15
2021
|
Eva Renee Barnett Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
143,000
+41.39%
|
-
|
|
Oct 04
2021
|
Eva Renee Barnett Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
59,500
+50.0%
|
-
|
|
Aug 27
2021
|
Douglas J. Hughes Director |
BUY
Open market or private purchase
|
Direct |
18,247
+23.79%
|
$145,976
$8.24 P/Share
|
|
Aug 20
2021
|
George V Migausky Director |
BUY
Open market or private purchase
|
Direct |
7,000
+9.43%
|
$49,000
$7.65 P/Share
|
|
Aug 13
2021
|
Atul Pande Director |
BUY
Open market or private purchase
|
Indirect |
5,000
+9.96%
|
$35,000
$7.98 P/Share
|
|
Aug 10
2021
|
Andrew J. Fromkin Director |
BUY
Open market or private purchase
|
Direct |
5,500
+10.74%
|
$38,500
$7.9 P/Share
|
|
Aug 03
2021
|
Peter Salzmann Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
570,613
+44.8%
|
-
|
|
Aug 03
2021
|
Julia G. Butchko Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
285,306
+45.28%
|
-
|
|
Aug 02
2021
|
Roivant Sciences Ltd. |
BUY
Other acquisition or disposition
|
Direct |
17,021,276
+18.83%
|
-
|
|
Jun 11
2021
|
William L. Macias Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,045
+47.73%
|
-
|
|
Mar 19
2021
|
Julia G. Butchko Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,500
+47.81%
|
-
|
|
Mar 19
2021
|
Rita Jain Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
109,365
+45.81%
|
-
|
|
Mar 19
2021
|
Michael James Elliott Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
97,600
+50.0%
|
-
|
|
Mar 19
2021
|
Connealy Pamela Yanchik Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,200
+50.0%
|
-
|
|
Mar 19
2021
|
Peter Salzmann Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
132,500
+50.0%
|
-
|
|
Mar 19
2021
|
Andrew J. Fromkin Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,500
+27.83%
|
-
|
|
Mar 19
2021
|
Douglas J. Hughes Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,500
+27.83%
|
-
|
|
Mar 19
2021
|
Atul Pande Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,500
+27.83%
|
-
|
|
Mar 19
2021
|
Frank Torti Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,200
+28.74%
|
-
|
|
Mar 19
2021
|
George V Migausky Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,500
+20.48%
|
-
|
|
Jan 22
2021
|
Rita Jain Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
-
|